The latest group of winning technologies has a little something for everyone—from scientists at the lab bench to those in the clinic and even the classroom.
For the past decade, scientists have relied almost exclusively on CRISPR-Cas systems for genome editing. Now, a smaller but equally efficient nuclease is here to compete.
In this webinar, Cole Cheng and Connie Rich will discuss the advantages of novel miniaturized plasmids for streamlining preclinical and clinical gene therapy development.
Even as CRISPR-based tools become a lab staple, scientists strive to tackle the associated technological challenges to improve their efficacy and safety.